CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 59 enrolled
Drug / intervention
Valbenazinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05859698
NCT05859698Phase 4Completed
CompareCT.gov

A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia

Neurocrine Biosciences·interventional·Posted May 16, 2023·Updated Jan 16, 2026

In Brief

A Phase 4 clinical trial evaluating Valbenazine for Schizophrenia and 4 related conditions. Completed, enrolled 59 participants across 18 sites.

Detailed Summary

This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who are receiving valbenazine for up to 24 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
202420252026
First PostedMay 16, 2023
Enrollment StartMay 9, 2023
Primary CompletionDec 27, 2024
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 3.1 years ago

Interventions

Valbenazinedrug

Valbenazine capsules for oral administration